Bret Stephens’ Pharmapologetics
Now, when the demand for both innovation and access is high, it’s time to think outside the box and reevaluate the relationship between pharmaceutical drugs and the patent system. Perhaps a prize system is in order, or maybe a formal guarantee from firms receiving BARDA grants that the drugs will not be patented.Featured Publications
Chevron deference is running on fumes
CFPB Credit Card Late Fee Goes into Effect
Market Gateways, Not the EPA, Determine Power Sector Decarbonization